185 related articles for article (PubMed ID: 19633042)
1. An open-label, randomized phase II study of adecatumumab, a fully human anti-EpCAM antibody, as monotherapy in patients with metastatic breast cancer.
Schmidt M; Scheulen ME; Dittrich C; Obrist P; Marschner N; Dirix L; Schmidt M; Rüttinger D; Schuler M; Reinhardt C; Awada A
Ann Oncol; 2010 Feb; 21(2):275-282. PubMed ID: 19633042
[TBL] [Abstract][Full Text] [Related]
2. Phase IB study of the EpCAM antibody adecatumumab combined with docetaxel in patients with EpCAM-positive relapsed or refractory advanced-stage breast cancer.
Schmidt M; Rüttinger D; Sebastian M; Hanusch CA; Marschner N; Baeuerle PA; Wolf A; Göppel G; Oruzio D; Schlimok G; Steger GG; Wolf C; Eiermann W; Lang A; Schuler M
Ann Oncol; 2012 Sep; 23(9):2306-2313. PubMed ID: 22357251
[TBL] [Abstract][Full Text] [Related]
3. Phase II study of the human anti-epithelial cell adhesion molecule antibody adecatumumab in prostate cancer patients with increasing serum levels of prostate-specific antigen after radical prostatectomy.
Marschner N; Rüttinger D; Zugmaier G; Nemere G; Lehmann J; Obrist P; Baeuerle PA; Wolf A; Schmidt M; Abrahamsson PA; Reinhardt C; Heidenreich A
Urol Int; 2010; 85(4):386-95. PubMed ID: 20606402
[TBL] [Abstract][Full Text] [Related]
4. Overexpression of EpCAM in uterine serous papillary carcinoma: implications for EpCAM-specific immunotherapy with human monoclonal antibody adecatumumab (MT201).
El-Sahwi K; Bellone S; Cocco E; Casagrande F; Bellone M; Abu-Khalaf M; Buza N; Tavassoli FA; Hui P; Rüttinger D; Silasi DA; Azodi M; Schwartz PE; Rutherford TJ; Pecorelli S; Santin AD
Mol Cancer Ther; 2010 Jan; 9(1):57-66. PubMed ID: 20053761
[TBL] [Abstract][Full Text] [Related]
5. Primary cervical carcinoma cell lines overexpress epithelial cell adhesion molecule (EpCAM) and are highly sensitive to immunotherapy with MT201, a fully human monoclonal anti-EpCAM antibody.
Richter CE; Cocco E; Bellone S; Bellone M; Casagrande F; Todeschini P; Rüttinger D; Silasi DA; Azodi M; Schwartz PE; Rutherford TJ; Pecorelli S; Santin AD
Int J Gynecol Cancer; 2010 Dec; 20(9):1440-7. PubMed ID: 21370592
[TBL] [Abstract][Full Text] [Related]
6. Exchanging human Fcgamma1 with murine Fcgamma2a highly potentiates anti-tumor activity of anti-EpCAM antibody adecatumumab in a syngeneic mouse lung metastasis model.
Lutterbuese P; Brischwein K; Hofmeister R; Crommer S; Lorenczewski G; Petersen L; Lippold S; da Silva A; Locher M; Baeuerle PA; Schlereth B
Cancer Immunol Immunother; 2007 Apr; 56(4):459-68. PubMed ID: 16937114
[TBL] [Abstract][Full Text] [Related]
7. Adecatumumab: an anti-EpCAM monoclonal antibody, from the bench to the bedside.
Kurtz JE; Dufour P
Expert Opin Biol Ther; 2010 Jun; 10(6):951-8. PubMed ID: 20426706
[TBL] [Abstract][Full Text] [Related]
8. A phase I study with adecatumumab, a human antibody directed against epithelial cell adhesion molecule, in hormone refractory prostate cancer patients.
Oberneder R; Weckermann D; Ebner B; Quadt C; Kirchinger P; Raum T; Locher M; Prang N; Baeuerle PA; Leo E
Eur J Cancer; 2006 Oct; 42(15):2530-8. PubMed ID: 16930989
[TBL] [Abstract][Full Text] [Related]
9. Drug evaluation: adecatumumab, an engineered human anti-EpCAM antibody.
Kirman I; Whelan RL
Curr Opin Mol Ther; 2007 Apr; 9(2):190-6. PubMed ID: 17458174
[TBL] [Abstract][Full Text] [Related]
10. High-grade, chemotherapy-resistant ovarian carcinomas overexpress epithelial cell adhesion molecule (EpCAM) and are highly sensitive to immunotherapy with MT201, a fully human monoclonal anti-EpCAM antibody.
Richter CE; Cocco E; Bellone S; Silasi DA; Rüttinger D; Azodi M; Schwartz PE; Rutherford TJ; Pecorelli S; Santin AD
Am J Obstet Gynecol; 2010 Dec; 203(6):582.e1-7. PubMed ID: 20870202
[TBL] [Abstract][Full Text] [Related]
11. Antibody Based EpCAM Targeted Therapy of Cancer, Review and Update.
Eyvazi S; Farajnia S; Dastmalchi S; Kanipour F; Zarredar H; Bandehpour M
Curr Cancer Drug Targets; 2018; 18(9):857-868. PubMed ID: 29295696
[TBL] [Abstract][Full Text] [Related]
12. Monoclonal antibody therapy with edrecolomab in breast cancer patients: monitoring of elimination of disseminated cytokeratin-positive tumor cells in bone marrow.
Braun S; Hepp F; Kentenich CR; Janni W; Pantel K; Riethmüller G; Willgeroth F; Sommer HL
Clin Cancer Res; 1999 Dec; 5(12):3999-4004. PubMed ID: 10632331
[TBL] [Abstract][Full Text] [Related]
13. Treatment of non-small cell lung cancer patients with the trifunctional monoclonal antibody catumaxomab (anti-EpCAM x anti-CD3): a phase I study.
Sebastian M; Passlick B; Friccius-Quecke H; Jäger M; Lindhofer H; Kanniess F; Wiewrodt R; Thiel E; Buhl R; Schmittel A
Cancer Immunol Immunother; 2007 Oct; 56(10):1637-44. PubMed ID: 17410361
[TBL] [Abstract][Full Text] [Related]
14. Clinical effects of a chimeric anti-EpCAM monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor in patients with metastatic colorectal carcinoma.
Liljefors M; Nilsson B; Fagerberg J; Ragnhammar P; Mellstedt H; Frödin JE
Int J Oncol; 2005 Jun; 26(6):1581-9. PubMed ID: 15870873
[TBL] [Abstract][Full Text] [Related]
15. Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer.
Blackwell KL; Burstein HJ; Storniolo AM; Rugo H; Sledge G; Koehler M; Ellis C; Casey M; Vukelja S; Bischoff J; Baselga J; O'Shaughnessy J
J Clin Oncol; 2010 Mar; 28(7):1124-30. PubMed ID: 20124187
[TBL] [Abstract][Full Text] [Related]
16. Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy.
Burris HA; Rugo HS; Vukelja SJ; Vogel CL; Borson RA; Limentani S; Tan-Chiu E; Krop IE; Michaelson RA; Girish S; Amler L; Zheng M; Chu YW; Klencke B; O'Shaughnessy JA
J Clin Oncol; 2011 Feb; 29(4):398-405. PubMed ID: 21172893
[TBL] [Abstract][Full Text] [Related]
17. Side-by-side analysis of five clinically tested anti-EpCAM monoclonal antibodies.
Münz M; Murr A; Kvesic M; Rau D; Mangold S; Pflanz S; Lumsden J; Volkland J; Fagerberg J; Riethmüller G; Rüttinger D; Kufer P; Baeuerle PA; Raum T
Cancer Cell Int; 2010 Nov; 10():44. PubMed ID: 21044305
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic potential of amanitin-conjugated anti-epithelial cell adhesion molecule monoclonal antibody against pancreatic carcinoma.
Moldenhauer G; Salnikov AV; Lüttgau S; Herr I; Anderl J; Faulstich H
J Natl Cancer Inst; 2012 Apr; 104(8):622-34. PubMed ID: 22457476
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic window of MuS110, a single-chain antibody construct bispecific for murine EpCAM and murine CD3.
Amann M; Brischwein K; Lutterbuese P; Parr L; Petersen L; Lorenczewski G; Krinner E; Bruckmeier S; Lippold S; Kischel R; Lutterbuese R; Kufer P; Baeuerle PA; Schlereth B
Cancer Res; 2008 Jan; 68(1):143-51. PubMed ID: 18172306
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetic and safety study of subcutaneously administered weekly ING-1, a human engineere monoclonal antibody targeting human EpCAM, in patients with advanced solid tumors.
Goel S; Bauer RJ; Desai K; Bulgaru A; Iqbal T; Strachan BK; Kim G; Kaubisch A; Vanhove GF; Goldberg G; Mani S
Ann Oncol; 2007 Oct; 18(10):1704-7. PubMed ID: 17693421
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
